Edgewood Oncology - Series A Investment, Mar 25, 2024
Edgewood Oncology secures $20 million in Series A financing to advance BTX-A51, a promising multi-kinase inhibitor targeting cancer master regulators, in AML and breast cancer. Acquired from Yissum, BTX-A51 shows early efficacy in Phase 1 trials. Phase 2a enrollment is ongoing for AML, with a breast cancer study starting in Q2 2024. The funding allows Edgewood to pursue clinical studies through 2026, focusing on precision medicine to address unmet medical needs.
Full Article: https://finance.yahoo.com/news/edgewood-oncology-emerges-stealth-20-160000890.html
Replimmune Group - Executive Changes, Mar 26, 2024
Replimune Group, Inc. announced strategic leadership changes to support the upcoming commercialization of its flagship product, RP1, pending regulatory approval. Sushil Patel, Ph.D., will replace Philip Astley-Sparke as CEO, with Astley-Sparke transitioning to Executive Chairman. Patel, with extensive biotech experience, will lead the company's growth into commercialization. The transition aligns with preparations for RP1's biologics license application (BLA) submission in late 2024. Additionally, other executive changes include Robert Coffin assuming an advisory role as Founder and Chief Scientist, Paul Bullock becoming Chief Manufacturing Officer, and departures of Pamela Esposito and Tanya Lewis from executive positions. Colin Love, Ph.D., Chief Operations Officer, and co-founder, will retire, with Bullock assuming oversight of manufacturing operations. These changes aim to bolster Replimune's capabilities for its next phase, marked by potential product launch and commercialization efforts.
Neogap Therapeutics - Grant, Mar 26, 2024
Neogap Therapeutics secures SEK 5 million Eurostars funding to collaborate with Okomera, a French biotech company, on refining T-cell activity analysis for cancer treatment. Neogap's personalized cell therapy, pTTL, targets colorectal cancer, while Okomera's method enhances understanding of T-cell interactions with tumors, aiming to predict therapy effectiveness, advancing precision medicine.
Full Article: https://news.cision.com/neogap-therapeutics-ab/r/neogap-secures-eurostars-funding-to-develop-t-cell-activity-analysis,c3951209
Merck - Drug Approval, Mar 28, 2024
Merck's Keytruda wins European approval for treating resectable non-small cell lung cancer alongside chemotherapy, marking the first such approval in the region. The decision, based on positive Phase III trial results, expands Keytruda's lung cancer indications in Europe to six. Despite being a leading cause of global cancer deaths, Keytruda continues to drive significant sales for Merck, with efforts underway to bolster its oncology portfolio amidst looming patent challenges.
Full Article: https://www.biospace.com/article/eu-approves-merck-s-keytruda-chemo-combo-for-lung-cancer-/
Tevogen Bio Holdings - Series A Investment shift, Mar 28, 2024
Tevogen Bio Holdings has struck a securities purchase deal with an existing investor, shifting from Series A Preferred Stock to Series A-1 Preferred Stock for $6.0 million. Dr. Manmohan Patel, an investor, expressed confidence in Tevogen's T cell platform and AI initiatives. CEO Dr. Ryan Saadi emphasized the importance of a supportive long-term partner. The Series A-1 Preferred Stock offers convertible terms at $10.00, with a 5% cumulative dividend and no mandatory redemption.
Full Article: https://www.biospace.com/article/releases/tevogen-bio-reports-series-a-1-preferred-stock-investment-at-10-conversion-price/
Xilio Therapeutics - Private Equity Funding, Mar 28, 2024
Xilio Therapeutics has announced a strategic portfolio reprioritization emphasizing the advancement of clinical-stage programs for XTX301 and XTX101, alongside leveraging its research platform for tumor-activated bispecific and cell engager molecules. The company reported additional Phase 2 data for XTX202, supporting its potential as combination therapy, while discontinuing monotherapy development. Xilio anticipates its cash runway extending into Q2 2025, facilitated by a private placement of equity. Additionally, Xilio has entered into an exclusive license agreement with Gilead Sciences for its tumor-activated IL-12 program. The company plans to reprioritize resources, including a workforce reduction, to align with its revised strategic focus, with estimated cash and equivalents sufficient to fund operations into Q2 2025.
Full Article: https://www.biospace.com/article/releases/xilio-therapeutics-announces-11-3-million-private-placement-equity-financing/
Mythic Therapeutics - Executive Changes, Mar 28, 2024
Mythic Therapeutics, a biotech company specializing in antibody-drug conjugate (ADC) therapies for cancer treatment, has appointed George Eliades, Ph.D., as its President and CEO. With extensive experience in corporate strategy and oncology medicine development, Dr. Eliades joins from Jazz Pharmaceuticals, where he led significant acquisitions and licensing agreements. His leadership aims to accelerate the clinical development of Mythic's lead therapeutic candidate, MYTX-011, and expand the company's ADC-focused pipeline, promising innovative solutions for cancer patients.
Full Article: https://mythictx.com/2024/03/28/mythic-therapeutics-appoints-george-eliades-ph-d-as-president-and-chief-executive-officer/
Kelonia Therapeutics - Executive Changes, Mar 28, 2024
Kelonia Therapeutics has appointed Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors. Dr. Hege, with extensive experience in hematology and oncology research, led the development of a CAR-T cell therapy to FDA approval. Dr. Mammen, CEO at FogPharma, brings expertise in pharmaceutical R&D, including COVID vaccine development. These appointments signal Kelonia's dedication to advancing in vivo gene delivery technology for oncology treatments.
Full Article: https://keloniatx.com/kelonia-therapeutics-appoints-kristen-hege-md-and-mathai-mammen-md-phd-to-board-of-directors/
Aveo Oncology - Executive Changes, Mar 29, 2024
AVEO Oncology has appointed Edgar E. Braendle, MD, PhD, as its new Chief Medical Officer, bringing over twenty years of clinical research experience to the leadership team. Dr. Braendle's previous roles include Chief Development Officer at Autolus Therapeutics Plc, where he oversaw pivotal programs in immunotherapy for leukemia, and Executive Vice President at Sumitomo Dainippon Pharma Oncology. AVEO also announced the formation of a Scientific Advisory Committee comprised of oncology experts to advise on clinical strategy and business development initiatives, aiming to bolster the company's position as a global oncology leader.
Full Article: https://finance.yahoo.com/news/correction-aveo-oncology-announces-appointment-192200648.html
